HTML preprocessors can make writing HTML more powerful or convenient. For instance, Markdown is designed to be easier to write and read for text documents and you could write a loop in Pug.
In CodePen, whatever you write in the HTML editor is what goes within the <body>
tags in a basic HTML5 template. So you don't have access to higher-up elements like the <html>
tag. If you want to add classes there that can affect the whole document, this is the place to do it.
In CodePen, whatever you write in the HTML editor is what goes within the <body>
tags in a basic HTML5 template. If you need things in the <head>
of the document, put that code here.
The resource you are linking to is using the 'http' protocol, which may not work when the browser is using https.
CSS preprocessors help make authoring CSS easier. All of them offer things like variables and mixins to provide convenient abstractions.
It's a common practice to apply CSS to a page that styles elements such that they are consistent across all browsers. We offer two of the most popular choices: normalize.css and a reset. Or, choose Neither and nothing will be applied.
To get the best cross-browser support, it is a common practice to apply vendor prefixes to CSS properties and values that require them to work. For instance -webkit-
or -moz-
.
We offer two popular choices: Autoprefixer (which processes your CSS server-side) and -prefix-free (which applies prefixes via a script, client-side).
Any URLs added here will be added as <link>
s in order, and before the CSS in the editor. You can use the CSS from another Pen by using its URL and the proper URL extension.
You can apply CSS to your Pen from any stylesheet on the web. Just put a URL to it here and we'll apply it, in the order you have them, before the CSS in the Pen itself.
You can also link to another Pen here (use the .css
URL Extension) and we'll pull the CSS from that Pen and include it. If it's using a matching preprocessor, use the appropriate URL Extension and we'll combine the code before preprocessing, so you can use the linked Pen as a true dependency.
JavaScript preprocessors can help make authoring JavaScript easier and more convenient.
Babel includes JSX processing.
Any URL's added here will be added as <script>
s in order, and run before the JavaScript in the editor. You can use the URL of any other Pen and it will include the JavaScript from that Pen.
You can apply a script from anywhere on the web to your Pen. Just put a URL to it here and we'll add it, in the order you have them, before the JavaScript in the Pen itself.
If the script you link to has the file extension of a preprocessor, we'll attempt to process it before applying.
You can also link to another Pen here, and we'll pull the JavaScript from that Pen and include it. If it's using a matching preprocessor, we'll combine the code before preprocessing, so you can use the linked Pen as a true dependency.
Search for and use JavaScript packages from npm here. By selecting a package, an import
statement will be added to the top of the JavaScript editor for this package.
Using packages here is powered by esm.sh, which makes packages from npm not only available on a CDN, but prepares them for native JavaScript ESM usage.
All packages are different, so refer to their docs for how they work.
If you're using React / ReactDOM, make sure to turn on Babel for the JSX processing.
If active, Pens will autosave every 30 seconds after being saved once.
If enabled, the preview panel updates automatically as you code. If disabled, use the "Run" button to update.
If enabled, your code will be formatted when you actively save your Pen. Note: your code becomes un-folded during formatting.
Visit your global Editor Settings.
<body>
<!--[if lt IE 8]>
<p class="browserupgrade">You are using an <strong>outdated</strong> browser. Please <a href="http://browsehappy.com/">upgrade your browser</a> to improve your experience.</p>
<![endif]-->
<header id="mastHead">
<div class="flex-container">
<div class="flex-row justify-content-center">
<div class="flex-col-sm-9">
<article>
<ul class="accordion" data-speed="150">
<li class="accordion-item">
<h3 class="accordion-title">L’IL-6, une cytokine <br class="mobile"> pléiotropique</h3>
<div class="accordion-content">
<p>L'IL-6 est une cytokine pléiotropique impliquée dans de multiples fonctions
physiologiques comme la réponse anti-infectieuse, la régulation du système
immunitaire via la production d’anticorps, la régulation du métabolisme osseux,
lipidique et glucidique, l’hématopoïèse ou le système neuroendocrinien <sup>(1, 2, 3, 4)</sup>.
</p>
<p>L’IL-6 a un rôle central dans la régulation de l’activité des cellules de l’immunité
innée et adaptative en réponse aux infections virales, parasitaires et bactériennes <sup>(1)</sup>.
</p>
</div>
</li>
<li class="accordion-item">
<h3 class="accordion-title">L’IL-6 dans <br class="mobile">l’immunité innée : <br class="mobile"><span class="font-normal">première ligne <br class="mobile">de défense</span></h3>
<div class="accordion-content">
<p>Au cours de l'inflammation aiguë, de nombreuses cellules de l’immunité innée, les
monocytes, les macrophages et les cellules endothéliales, produisent l'IL-6, ce qui
entraîne le recrutement de neutrophiles à travers l'activation d'un sous-ensemble de
chimiokines et de molécules d'adhésion par les cellules endothéliales, les cellules
musculaires lisses et les fibroblastes <sup>(5)</sup>.
</p>
<p>Ces cellules de l’immunité innée répondent aussi à l’IL-6, ce qui crée une boucle
autocrine qui amplifie la réponse inflammatoire <sup>(5)</sup>.
</p>
</div>
</li>
<li class="accordion-item">
<h3 class="accordion-title">L’IL-6 dans l’immunité<br class="mobile"> adaptative : <span class="font-normal">seconde<br class="mobile"> ligne de défense</span></h3>
<div class="accordion-content">
<p>L'IL-6 stimule l’activité lymphocytaire et la production d’anticorps, stimule
l’activation des lymphocytes Th17 et inhibe les lymphocytes T régulateurs <sup>(3, 6)</sup>.
</p>
<p class="text-center schema_title mt-20 mb-20">Adapté de Calabrese et Rose-John, 2014, et Dayer et Choy, 2010</p>
<p class="text-center"><img src="https://images.unsplash.com/photo-1593642532842-98d0fd5ebc1a?ixid=MnwxMjA3fDF8MXxhbGx8MTZ8fHx8fHwyfHwxNjE4MTA0Njc5&ixlib=rb-1.2.1&dpr=1&auto=format&fit=crop&w=120&h=200&q=60" class="" alt="schéma IL-6"></p>
<p class="text-center mt-50"><a id="myBtn" class="popup desktop" href="#">Agrandir le schéma</a></p>
<!-- The Modal -->
<div id="myModal" class="modal desktop">
<a class="close" href="#">X</a>
<div class="modal-content">
<p class="text-center"><img src="https://images.unsplash.com/photo-1593642532842-98d0fd5ebc1a?ixid=MXwxMjA3fDF8MHxwaG90by1wYWdlfHx8fGVufDB8fHw%3D&ixlib=rb-1.2.1&auto=format&fit=crop&w=750&q=80" alt=""></p>
</div>
</div>
<p class="text-center mt-50"><a id="myBtnMobile" class="popup mobile" href="#">Agrandir le schéma</a></p>
<div id="myModalMobile" class="modal mobile">
<div class="modal-content">
<a class="close" href="#">X</a>
<p class="text-center"><img src="https://images.unsplash.com/photo-1593642533144-3d62aa4783ec?ixid=MXwxMjA3fDF8MHxwaG90by1wYWdlfHx8fGVufDB8fHw%3D&ixlib=rb-1.2.1&auto=format&fit=crop&w=750&q=80" alt=""></p>
</div>
</div>
</div>
</li>
<li class="accordion-item">
<h3 class="accordion-title">Une cytokine au <br class="mobile">coeur de certaines <br class="mobile">pathologies</h3>
<div class="accordion-content">
<p>Dans les conditions physiologiques, les taux sériques d'IL-6 sont relativement faibles
(1 à 5 pg/ml), mais sont rapidement augmentés dans un contexte pathologique
notamment en cas d'infection, d'auto-immunité ou de cancer <sup>(1)</sup>.
</p>
<p>Lorsque les taux d'IL-6 sont élevés, l'homéostasie de nombreux processus
physiologiques peut être perturbée <sup>(1)</sup>.
</p>
</div>
</li>
<li class="accordion-item">
<h3 class="accordion-title">IL-6 et polyarthrite<br class="mobile"> rhumatoïde</h3>
<div class="accordion-content">
<p>Une élévation persistante d’IL-6 est un facteur clé de la physiopathogénie des
manifestations articulaires mais aussi des manifestations extra-articulaires de la PR
notamment les complications cardiovasculaires, l’anémie, la fatigue et
l’ostéoporose <sup>(11, 12)</sup>.
</p>
</div>
</li>
<li class="accordion-item">
<h3 class="accordion-title">IL-6 et réaction <br class="mobile">inflammatoire <br class="mobile">exacerbée<br/>
<span class="font-normal">syndrome de<br class="mobile"> relargage cytokinique</span>
</h3>
<div class="accordion-content">
<p>Le syndrome de relargage cytokinique (SRC) est une réponse inflammatoire
systémique qui peut être causée par une infection, certains médicaments et d'autres
facteurs <sup>(9)</sup>.
</p>
<p>Le SRC est caractérisé par une forte augmentation du niveau d'un grand nombre de
cytokines pro-inflammatoires <sup>(9)</sup>.
</p>
<p>Le SRC est plus fréquent dans les maladies du système immunitaire, dans les
immuno-thérapies (telles que la thérapie cellulaire CAR-T), la septicémie liée à la
transplantation d'organe ou en cas d’infection virale <sup>(9)</sup>.
</p>
<p>Le SRC peut se présenter sous une variété de symptômes allant de symptômes
pseudo-grippaux légers à de graves manifestations potentiellement mortelles dus à
la réponse inflammatoire excessive <sup>(10)</sup>.
</p>
<p>Les symptômes bénins du SRC comprennent la fièvre, la fatigue, les maux de tête, les
éruptions cutanées, l'arthralgie et les myalgies. Les cas plus graves sont caractérisés
par une hypotension ainsi qu'une fièvre élevée et peuvent évoluer vers une réponse
inflammatoire systémique incontrôlée avec un choc circulatoire nécessitant un
vasopresseur, une fuite vasculaire, une coagulation intravasculaire disséminée et une
défaillance multiple des organes. Les anomalies de laboratoire qui sont courantes
chez les patients atteints de SRC comprennent des cytopénies, une élévation de la
créatinine et des enzymes hépatiques, des paramètres de coagulation perturbés et
un taux de CRP élevé <sup>(10)</sup>.
</p>
</div>
</li>
<li class="accordion-item">
<h3 class="accordion-title">La voie de signalisation <br class="mobile">de l’IL-6</h3>
<div class="accordion-content">
<p>L'IL-6 se lie à son récepteur membranaire exprimé par plusieurs cellules de
l’organisme notamment les monocytes, les macrophages et les fibroblastes ou
soluble. L'IL-6 peut aussi se lier à une forme soluble circulante de son récepteur <sup>(8)</sup>.
</p>
<p>Le complexe IL-6/récepteur se lie à son tour à la protéine GP130, protéine ubiquitaire
exprimée par quasiment la totalité des cellules de l’organisme <sup>(8)</sup>.
</p>
<p>Le complexe IL-6/récepteur/GP130 ainsi formé, déclenche une cascade de
signalisations intracellulaires à l’origine de l’activation de certains gènes notamment
les gènes codant des protéines de la phase aiguë de l’inflammation <sup>(8)</sup>.
</p>
</div>
</li>
</ul>
</article>
<section>
<div class="reference-item">
<h3 class="reference-title">Bibliographie</h3>
<div class="reference-content">
<ol>
<li>Hunter <em>et al.</em> IL-6 as a keystone cytokine in health and disease.<em> Nat Immunol</em> 2015; 16 :448–457.</li>
<li>Jones <em>et al.</em> Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. <em>Nat Rev Immunol</em> 2018; 18: 773–789.</li>
<li>Kimura <em>et al.</em> IL-6: Regulator of Treg/Th17 balance. <em>European Journal of Immunology</em> 2010; 40(7): 1830–1835.
</li>
<li>Kishimoto <em>et al.</em> IL-6: From its discovery to clinical applications. <em>International Immunology</em> 2010; 22(5): 347–352.</li>
<li>Choy <em>et al.</em> Interleukin-6 as a multifunctional regulator: inflammation, immune response, and fibrosis. <em>J Scleroderma Relat Disord</em> 2017; 2(Suppl 2): S1-S5.</li>
<li>Luo et Zheng. Hall of Fame among Pro-inflammatory Cytokines: Interleukin-6 Gene and Its Transcriptional Regulation Mechanisms. <em>Front Immunol</em> 2016; 19;7:604.</li>
<li>Choy. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. <em>Rheumatology</em> 2012; 51:v3-v11.</li>
<li>Choy. Translating IL-6 biology into effective treatments. <em>Nat Rev Rheumatol</em> 2020: 16(6):335-345.</li>
<li>Zhang <em>et al.</em> The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. <em>Int J Antimicrob Agents</em> 2020: 10595.</li>
<li>Shimabukuro-Vornhagen <em>et al.</em> Cytokine release syndrome.<em> J Immunother Cancer</em> 2018; 6: 56.</li>
<li>Dayer et Choy. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. <em>Rheumatology</em> 2010; 49:15–24.</li>
<li>Référence schéma : Calabrese et Rose-John. IL‑6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014; 10(12):720-7 et Dayer et Choy. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. <em>Rheumatology</em> 2010; 49: 15-24.</li>
</ol>
</div>
</div>
</section>
</div>
</div>
<!-- #main -->
</div>
<!-- #main-container -->
</body>
html {
color: #222;
font-size: 1em;
line-height: 1.4;
min-height:100%;
}
body{
font-size: 16px;
line-height:26px;
font-family: Helvetica, Helvetica Neue, Arial;
min-height:100%;
}
::-moz-selection {
background: #b3d4fc;
text-shadow: none;
}
::selection {
background: #b3d4fc;
text-shadow: none;
}
hr {
display: block;
height: 1px;
border: 0;
border-top: 1px solid #ccc;
margin: 1em 0;
padding: 0;
}
audio,
canvas,
iframe,
img,
svg,
video {
vertical-align: middle;
}
fieldset {
border: 0;
margin: 0;
padding: 0;
}
textarea {
resize: vertical;
}
.browserupgrade {
margin: 0.2em 0;
background: #ccc;
color: #000;
padding: 0.2em 0;
}
/* ===== grid ==================== */
.flex-container {
-webkit-box-sizing: border-box;
box-sizing: border-box;
margin: 0 auto;
padding: 0 1em;
}
@media (min-width: 540px) {
.flex-container {
max-width: 540px;
}
}
@media (min-width: 768px) {
.flex-container {
max-width: 768px;
}
}
@media (min-width: 992px) {
.flex-container {
max-width: 992px;
}
}
@media (min-width: 1200px) {
.flex-container {
max-width: 1200px;
}
}
.flex-row {
-webkit-box-sizing: border-box;
box-sizing: border-box;
display: -webkit-box;
display: -ms-flexbox;
display: flex;
-ms-flex-wrap: wrap;
flex-wrap: wrap;
margin-bottom: 1em;
}
.flex-col-xs-9, .flex-col-sm-9, .flex-col-md-9, .flex-col-lg-9 {
-webkit-box-sizing: border-box;
box-sizing: border-box;
padding: 1em 1.4em;
width: 100%;
}
@media (min-width: 540px) {
.flex-col-xs-9 {
max-width: calc(100% * (9 / 12));
width: calc(100% * (9 / 12));
}
}
@media (min-width: 768px) {
.flex-col-sm-9 {
max-width: calc(100% * (9 / 12));
width: calc(100% * (9 / 12));
}
}
@media (min-width: 992px) {
.flex-col-md-9 {
max-width: calc(100% * (9 / 12));
width: calc(100% * (9 / 12));
}
}
@media (min-width: 1200px) {
.flex-col-lg-9 {
max-width: calc(100% * (9 / 12));
width: calc(100% * (9 / 12));
}
}
@media (min-width: 768px) {
.justify-content-center {
-webkit-box-pack: center;
-ms-flex-pack: center;
justify-content: center
}
}
/* ==============
HEADER
============== */
.featured-img{
display:-webkit-box;
display:-ms-flexbox;
display:flex;
-webkit-box-pack:center;
-ms-flex-pack:center;
justify-content:center;
}
.featured-img img{
max-width:415px;
width:100%;
}
.logo_genzyme{
text-align:center;
}
.center{
-webkit-box-pack:center;
-ms-flex-pack:center;
justify-content:center;
}
/* ==============
COMPONENT
============== */
.text-center{
text-align:center;
}
.font-normal{
font-weight:normal;
}
.mt-20 {
margin-top:20px;
}
.mt-30 {
margin-top:30px;
}
.mt-50{
margin-top:50px;
}
.mb-20{
margin-bottom:20px;
}
img{
max-width:100%;
}
.desktop{
display:none;
}
/* ==============
ACCORDION
============== */
.accordion {
padding: 0;
list-style: none;
}
.accordion li{
margin:40px auto;
}
.accordion-title{
color:#892b7d;
padding:35px 0 15px;
border-bottom:2px solid #892b7d;
position:relative;
cursor:pointer;
font-size:20px;
}
.accordion-title::before{
content:'';
position:absolute;
width:140px;
height:10px;
border-bottom-left-radius:12px;
border-bottom-right-radius:12px;
background-color: #892b7d;
top:100%;
}
.accordion-title::after{
content:'';
background:url(../img/fleche_open.jpg);
position:absolute;
right:0;
top: 80%;
width:24px;
height:14px;
-webkit-transition:0.3s;
-o-transition:0.3s;
transition:0.3s;
}
.active .accordion-title::after{
-webkit-transform:rotate(180deg);
-ms-transform:rotate(180deg);
transform:rotate(180deg);
}
.accordion-content{
padding-top:20px;
}
/* ==============
SCHEMA SECTION
============== */
.popup{
color:#892b7d;
border:2px solid #892b7d;
padding:25px 35px;
border-radius:12px;
text-decoration:none;
}
.schema_title{
color:#892b7d;
font-weight:bold;
}
.schema_img{
max-width:800px;
margin:0 auto;
width: 100%;
}
/* ==============
SECTION REFERENCE
============== */
.reference-item{
margin:40px auto;
}
.reference-title{
padding:35px 0;
border-bottom:2px solid #892b7d;
position:relative;
font-size:20px;
color:#892b7d;
}
.reference-title::before{
content:'';
position:absolute;
width:140px;
height:10px;
border-bottom-left-radius:12px;
border-bottom-right-radius:12px;
background-color: #892b7d;
top:100%;
}
.reference-content{
padding-top:20px;
}
.reference-content ol {
counter-reset: section;
padding-left:0;
}
.reference-content li{
list-style: none;
position:relative;
padding-left: 40px;
margin-bottom:15px;
font-size:14px;
}
.reference-content li::before {
counter-increment: section;
content: "("counter(section)") ";
position: absolute;
top: 0;
left: 0px;
}
/* ==============
POPUP
============== */
.close {
color: #aaaaaa;
float: right;
font-size: 28px;
font-weight: bold;
text-decoration: none;
margin: 20px;
}
.close:hover,
.close:focus {
color: #000;
text-decoration: none;
cursor: pointer;
}
.modal {
visibility: hidden;
-webkit-backface-visibility: hidden;
backface-visibility: hidden;
position: fixed;
z-index: 999;
left: 0;
top: 0;
width: 100%;
height: 100%;
background-color: #ffffff;
overflow:auto;
}
.modal-content {
-webkit-transform: scale(0.7);
-ms-transform: scale(0.7);
transform: scale(0.7);
opacity: 0;
-webkit-transition: all 0.3s;
-o-transition: all 0.3s;
transition: all 0.3s;
padding: 20px;
}
.show .modal-content{
-webkit-transform: scale(1);
-ms-transform: scale(1);
transform: scale(1);
opacity: 1;
height: 100%;
}
.modal::before{
content:'';
position:absolute;
width:260px;
height:10px;
border-bottom-right-radius:12px;
background-color: #892b7d;
top:0;
left:0;
}
.show{
visibility: visible;
}
#myModalMobile img{
width: 100%;
height: 100%;
}
.ie7 .title {
padding-top: 20px;
}
/* ==========================================================================
Media Queries
========================================================================== */
@media only screen and (min-width: 48em) {
.logo img{
max-width:298px;
}
}
@media only screen and (min-width: 62em) {
.featured-img img{
margin-top:-125px;
}
.desktop{
display:inline-block;
}
.mobile{
display:none;
}
.accordion-title{
padding:35px 0;
}
.accordion-title::before{
width:260px;
}
.reference-title::before{
width:260px;
}
.accordion-title::after{
top:50%;
-webkit-transform:translateY(-50%);
-ms-transform:translateY(-50%);
transform:translateY(-50%);
}
.space-between{
-webkit-box-pack:justify;
-ms-flex-pack:justify;
justify-content:space-between;
}
.modal::after{
content:'';
position:absolute;
width:260px;
height:10px;
border-top-left-radius:12px;
background-color: #892b7d;
right:0;
bottom:0;
}
.show .modal-content{
display: -webkit-box;
display: -ms-flexbox;
display: flex;
-webkit-box-pack: center;
-ms-flex-pack: center;
justify-content: center;
-webkit-box-align: center;
-ms-flex-align: center;
align-items: center;
}
.modal {
overflow:hidden
}
}
/* ====== Helper classes ============= */
.clearfix:before,
.clearfix:after {
content: " ";
display: table;
}
.clearfix:after {
clear: both;
}
.clearfix {
*zoom: 1;
}
$('.accordion').each(function(e) {
var accordion = $(this);
var toggleSpeed = accordion.attr('data-speed') || 100;
function open(item, speed) {
accordion.find('.accordion-item').not(item).removeClass('active')
.find('.accordion-content').slideUp(speed);
item.addClass('active')
.find('.accordion-content').slideDown(speed);
}
open(accordion.find('.active:first'), 0);
accordion.on('click', '.accordion-title', function(ev) {
ev.preventDefault();
open($(this).closest('.accordion-item'), toggleSpeed);
});
});
jQuery( document ).ready(function() {
$('#myBtn').click(function(e){
$('#myModal').toggleClass("show");
e.preventDefault();
})
$('#myBtnMobile').click(function(e){
$('#myModalMobile').toggleClass("show");
e.preventDefault();
})
$('.close').click(function(e){
$('#myModal').toggleClass("show");
$('#myModalMobile').toggleClass("show");
e.preventDefault();
})
})
Also see: Tab Triggers